593 related articles for article (PubMed ID: 28612285)
1. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis.
Rocha ALL; Faria LC; Guimarães TCM; Moreira GV; Cândido AL; Couto CA; Reis FM
J Endocrinol Invest; 2017 Dec; 40(12):1279-1288. PubMed ID: 28612285
[TBL] [Abstract][Full Text] [Related]
2. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease.
Kim JJ; Kim D; Yim JY; Kang JH; Han KH; Kim SM; Hwang KR; Ku SY; Suh CS; Kim SH; Choi YM
Aliment Pharmacol Ther; 2017 Jun; 45(11):1403-1412. PubMed ID: 28370150
[TBL] [Abstract][Full Text] [Related]
3. Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a United Kingdom primary care database.
Kumarendran B; O'Reilly MW; Manolopoulos KN; Toulis KA; Gokhale KM; Sitch AJ; Wijeyaratne CN; Coomarasamy A; Arlt W; Nirantharakumar K
PLoS Med; 2018 Mar; 15(3):e1002542. PubMed ID: 29590099
[TBL] [Abstract][Full Text] [Related]
4. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?
Targher G; Rossini M; Lonardo A
Endocrine; 2016 Feb; 51(2):211-21. PubMed ID: 26024975
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome.
Macut D; Bjekić-Macut J; Livadas S; Stanojlović O; Hrnčić D; Rašić-Marković A; Milutinović DV; Mladenović V; Andrić Z
Curr Pharm Des; 2018; 24(38):4593-4597. PubMed ID: 30652641
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
[TBL] [Abstract][Full Text] [Related]
7. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.
Ayonrinde OT; Adams LA; Doherty DA; Mori TA; Beilin LJ; Oddy WH; Hickey M; Sloboda DM; Olynyk JK; Hart R
J Gastroenterol Hepatol; 2016 May; 31(5):980-7. PubMed ID: 26589977
[TBL] [Abstract][Full Text] [Related]
8. High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance.
Cai J; Wu CH; Zhang Y; Wang YY; Xu WD; Lin TC; Li SX; Wang LH; Zheng J; Sun Y; Liu W; Tao T
Int J Obes (Lond); 2017 Sep; 41(9):1341-1347. PubMed ID: 28487551
[TBL] [Abstract][Full Text] [Related]
9. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis.
Wu J; Yao XY; Shi RX; Liu SF; Wang XY
Reprod Health; 2018 May; 15(1):77. PubMed ID: 29747678
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: associated factors and noninvasive fibrosis staging in a single Brazilian center.
Taranto DOL; Guimarães TCM; Couto CA; Cândido AL; Azevedo RCS; Mattos FS; Elias MLC; Reis FM; Rocha ALL; Faria LC
Arch Endocrinol Metab; 2020; 64(3):235-242. PubMed ID: 32555989
[TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome - clinical and metabolic aspects and lipoprotein lipase gene polymorphism.
Bohdanowicz-Pawlak A; Lenarcik-Kabza A; Brona A; Kuliczkowska-Płaksej J; Łaczmański Ł; Zaleska-Dorobisz U; Milewicz A
Endokrynol Pol; 2014; 65(6):416-21. PubMed ID: 25554608
[TBL] [Abstract][Full Text] [Related]
12. Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Harsha Varma S; Tirupati S; Pradeep TVS; Sarathi V; Kumar D
Diabetes Metab Syndr; 2019; 13(2):1065-1069. PubMed ID: 31336445
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease is associated with hyperandrogenism in women with polycystic ovary syndrome.
Hong SH; Sung YA; Hong YS; Song DK; Jung H; Jeong K; Chung H; Lee H
Sci Rep; 2023 Aug; 13(1):13397. PubMed ID: 37591864
[TBL] [Abstract][Full Text] [Related]
14. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome.
Vassilatou E; Lafoyianni S; Vryonidou A; Ioannidis D; Kosma L; Katsoulis K; Papavassiliou E; Tzavara I
Hum Reprod; 2010 Jan; 25(1):212-20. PubMed ID: 19887498
[TBL] [Abstract][Full Text] [Related]
15. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
Jeanes YM; Reeves S
Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
[TBL] [Abstract][Full Text] [Related]
16. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.
Baranova A; Tran TP; Birerdinc A; Younossi ZM
Aliment Pharmacol Ther; 2011 Apr; 33(7):801-14. PubMed ID: 21251033
[TBL] [Abstract][Full Text] [Related]
17. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.
Polyzos SA; Goulis DG; Kountouras J; Mintziori G; Chatzis P; Papadakis E; Katsikis I; Panidis D
Hormones (Athens); 2014; 13(4):519-31. PubMed ID: 25402369
[TBL] [Abstract][Full Text] [Related]
18. Hepatic manifestations of women with polycystic ovary syndrome.
Chen MJ; Ho HN
Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():119-128. PubMed ID: 27107966
[TBL] [Abstract][Full Text] [Related]
19. Prevalence, etiology and management of non-alcoholic fatty liver disease in patients with polycystic ovary syndrome.
Makri E; Tziomalos K
Minerva Endocrinol; 2017 Jun; 42(2):122-131. PubMed ID: 27792214
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Paschou SA; Polyzos SA; Anagnostis P; Goulis DG; Kanaka-Gantenbein C; Lambrinoudaki I; Georgopoulos NA; Vryonidou A
Endocrine; 2020 Jan; 67(1):1-8. PubMed ID: 31538291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
